

PREFACE

When I accepted the role of editor-in-chief for *Annual Reports in Medicinal Chemistry*, I worked with the Executive Committee of the Division of Medicinal Chemistry (the actual owners of the book) to redefine the role of editor-in-chief. Through these efforts, we have made the position a defined responsibility for the Executive Committee and a position answerable to the Executive Committee. We changed the role of editor-in-chief to a position elected by the Executive Committee with a 5-year term and with an *ad hoc* appointment on the Executive Committee of the Medicinal Chemistry Division of the ACS. My term expires with the delivery of this volume, the 46th in the series. I want to thank Dave Rotella for recruiting me into this position, and the other members of the Executive Committee for supporting me throughout my 5-year term. It went by all too quickly. The new editor-in-chief (for Volumes 47–51) elected by the Executive Committee of our Division will be Manoj Desai, a friend and former colleague of mine and the very capable section editor of the “Topics in Drug Discovery” section for many years. I have no doubt that he will do an outstanding job continuing the excellence that has defined *Annual Reports in Medicinal Chemistry*. I wish him the very best in his new role. Thank you again to all who supported me in my role with “The Book”, especially you, the readers.

Annual Reports in Medicinal Chemistry has reached Volume 46. Its longevity continues to be a testament to the vitality of the field of medicinal chemistry, and I hope that *Annual Reports in Medicinal Chemistry* continues to be the review resource for medicinal chemists. Volume 46 upholds the traditions of *Annual Reports in Medicinal Chemistry* with 26 chapters covering the themes of central nervous system disease, cardiovascular and metabolic diseases, inflammation/pulmonary/GI, oncology, infectious disease, topics in biology, topics in drug design and discovery, and finally our review of new drugs introduced in 2010 in the “To Market, To Market” chapter.

With the field of medicinal chemistry suffering continued contraction in 2010 and 2011, it was a challenge to maintain the high energy of *Annual Reports in Medicinal Chemistry*, albeit one certainly worth the effort. A number of section editors and chapter authors have been affected by

the consolidation of the pharmaceutical industry and the field of medicinal chemistry in general, led by the business decisions of Pfizer, Merck, and other companies. The contraction of the pharmaceutical industry in the past 10–15 years has been dramatic. However, small molecules are still a main driver in extending and improving human health, and I don't doubt that a day in the near future will come when the industry realizes that it has cut back too much and that experienced medicinal chemists are worth their weight in gold.

Volume 46 of *Annual Reports in Medicinal Chemistry* is the result of the efforts of a stellar team comprised entirely of volunteers. I'd first like to thank all of the chapter authors in Volume 46 for their dedication and talent. They enthusiastically provided a consistent quality to the book. Helping bring all of this together were the section editors: Albert Robichaud, Andrew Stamford, David Weinstein, Shelli McAlpine, John Primeau, Manoj Desai, and John Lowe. I would like to thank them for their time and constant dedication. I'd like to welcome and thank a new team for our "To Market, To Market" chapter which covers the new molecular entities (NMEs) introduced in the past year (2010). Joanne Bronson and her coauthors Murali Dhar, Rick Ewing, and Nils Lonberg have taken on their new role in *Annual Reports in Medicinal Chemistry* with gusto and have closed the book with an excellent review of the drugs introduced in 2010. It has been my pleasure to be able to work with such a dedicated and talented group of section editors for my term. I cannot thank them enough for the time they have given to *Annual Reports in Medicinal Chemistry*. Finally, I'd like to thank my administrative assistant Cathy Hathaway for doing whatever has been needed to get the job done for the book.

Helping the section editors and me were a team of reviewers/proofreaders who have done another spectacular job behind the scenes as well. I would like to acknowledge these reviewers/proofreaders by listing their names below as a demonstration of our appreciation for their time and effort.

AstraZeneca—Greg Bisacchi and Art Patten

Bristol-Myers Squibb—Stephen Adams, Kenneth Boy, Peter Cheng, James J.-W. Duan, Andrew Degnan, Derek Denhart, Carolyn Dzierba, Bruce Ellsworth, Matthew Hill, Siew Peng Ho, John Hynes, John Kadow, George Karageorge, James Kempson, Dalton King, Lawrence Marcin, Richard Olson, James Sheppeck, Lawrence Snyder, Steven Spergel, Drew Thompson, William Washburn, Ryan Westphal, Mark Wittman, and Christopher Zusi

Eli Lilly and Company—Paul Ornstein

Gilead Sciences—Randall Halcomb, James Taylor, and Will Watkins

Lundbeck—Allen T. Hopper, John M. Peterson, and Andrew D. White

Monclair State University—David Rotella

Mnemosyne Pharmaceuticals—Bert Chenard

Pfizer—George Chang, Robert Dow, Brian O'Neill, and Ralph Robinson

In summary, I have tremendously enjoyed delivering Volumes 42–46 of *Annual Reports in Medicinal Chemistry* to you all, and I hope you have gotten much out of the series. I know that *Annual Reports in Medicinal Chemistry* will continue to be a key reference for your medicinal chemistry pursuits. Thank you to all who have contributed to this endeavor and its success.

John E. Macor, Ph.D.

Editor-in-Chief, *Annual Reports in Medicinal Chemistry* (Volumes 42–46)

Executive Director, Neuroscience Discovery Chemistry

Bristol-Myers Squibb, R&D

Wallingford, CT, USA

August 27th, 2011